Matthew Robson

Matthew Robson

Auto-generated profile, based on publicly available information

Matthew Robson

Autolus Therapeutics, London, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFMathieu Ferrari
Mathieu Ferrari
MRMatteo Righi
Matteo Righi
VBVania Baldan
Vania Baldan
PWPatrycja Wawrzyniecka
Patrycja Wawrzyniecka
ABAnna Bulek
Anna Bulek
MPMartin Pule
Martin Pule
Peripheral T cell lymphomas are typically aggressive with a poor prognosis. Unlike other hematologic malignancies, the lack of target antigens to discriminate healthy from malignant cells limits the efficacy of immunotherapeutic approaches. The T cell receptor expresses one of two highly homologous chains [T cell receptor β-chain constant (TRBC) domains 1 and 2] in a mutually exclusive manner, making it a promising target. Here we demonstrate specificity redirection by rational design using structure-guided computational biology to generate a TRBC2-specific antibody (KFN), complementing the antibody previously described by our laboratory with unique TRBC1 specificity (Jovi-1) in targeting broader spectrum of T cell malignancies clonally expressing either of the two chains. This permits generation of paired reagents (chimeric antigen receptor-T cells) specific for TRBC1 and TRBC2, with preclinical evidence to support their efficacy in T cell malignancies.

23 June 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MRMatteo Righi
Matteo Righi
IGIsaac Gannon
Isaac Gannon
MRMatthew Robson
Matthew Robson
SSSaket Srivastava
Saket Srivastava
EKEvangelia Kokalaki
Evangelia Kokalaki
MPMartin Pule
Martin Pule
Adoptive T-cell therapy aims to achieve lasting tumor clearance, requiring enhanced engraftment and survival of the immune cells. Cytokines are paramount modulators of T-cell survival and proliferation. Cytokine receptors signal via ligand-induced dimerization, and this principle has been hijacked utilizing nonnative dimerization domains. A major limitation of current technologies resides in the absence of a module that recapitulates the natural cytokine receptor heterodimeric pairing. To circumvent this, we created a new engineered cytokine receptor able to constitutively recreate receptor-heterodimer utilizing the heterodimerization domain derived from the IgG1 antibody (dFab_CCR). We found that the signal delivered by the dFab_CCR-IL2 proficiently mimicked the cytokine receptor heterodimerization, with transcriptomic signatures like those obtained by activation of the native IL2 receptor. Moreover, we found that this dimerization structure was agnostic, efficiently activating signaling through four cytokine receptor families. Using a combination of in vivo and in vitro screening approaches, we characterized a library of 18 dFab_CCRs coexpressed with a clinically relevant solid tumor–specific GD2-specific chimeric antigen receptor (CAR). Based on this characterization, we suggest that the coexpression of either the common β-chain GMCSF or the IL18 dFab_CCRs is optimal to improve CAR T-cell expansion, engraftment, and efficacy. Our results demonstrate how Fab dimerization is efficient and versatile in recapitulating a cytokine receptor heterodimerization signal. This module could be applied for the enhancement of adoptive T-cell therapies, as well as therapies based on other immune cell types. Furthermore, these results provide a choice of cytokine signal to incorporate with adoptive T-cell therapies.

16 September 2024
Verified
Other
Open access
PDF file
MRMatteo Righi
Matteo Righi
IGIsaac Gannon
Isaac Gannon
MRMathew Robson
Mathew Robson
SSSaket Srivastava
Saket Srivastava
EKEvangelia Kokalaki
Evangelia Kokalaki
MPMartin Pule
Martin Pule
Supplementary Table 1: Key Resources

19 July 2023
Verified
Other
Open access
PDF file
MRMatteo Righi
Matteo Righi
IGIsaac Gannon
Isaac Gannon
MRMatthew Robson
Matthew Robson
SSSaket Srivastava
Saket Srivastava
EKEvangelia Kokalaki
Evangelia Kokalaki
MPMartin Pule
Martin Pule
Supplementary Table S2. Top 50 up-regulated GSEA pathways.


26 November 2025
Verified
Other
Open access
PDF file
MRMatteo Righi
Matteo Righi
IGIsaac Gannon
Isaac Gannon
MRMatthew Robson
Matthew Robson
SSSaket Srivastava
Saket Srivastava
EKEvangelia Kokalaki
Evangelia Kokalaki
MPMartin Pule
Martin Pule
Supplementary Table S2. Top 50 up-regulated GSEA pathways.